Drobac Stephanie, Rubin Karen, Rogol Alan D, Rosenfield Robert L
Department of Pediatrics, University of Chicago, IL, USA.
J Pediatr Endocrinol Metab. 2006 Jan;19(1):55-64. doi: 10.1515/jpem.2006.19.1.55.
The optimal pubertal hormone replacement therapy in females and males is unclear.
To review hormone replacement options for hypogonadal teenagers and to determine the relevant attitudes and practices of pediatric endocrinologists in the United States.
DESIGN/METHODS: A workshop on pubertal hormone replacement options was held during the Lawson Wilkins Pediatric Endocrine Society meeting in 2004. A questionnaire was distributed to investigate the audience's attitudes and practices in inducing puberty.
The majority of respondents used conjugated estrogens to treat hypogonadal girls with the primary aim of treatment being attainment of maximal adult height. The majority of respondents used depot testosterone to treat hypogonadal boys with the primary aim of treatment being pubertal development and virilization.
The use of physiological sex hormone replacement to optimize the induction of puberty in hypogonadal adolescents was recommended. The workshop revealed striking differences between US and European pediatric endocrinologists regarding their practices and attitudes regarding the induction of puberty in hypogonadal females. Detailed studies are necessary to develop more uniform guidelines.
男女最佳的青春期激素替代疗法尚不清楚。
回顾性腺功能减退青少年的激素替代选择，并确定美国儿科内分泌学家的相关态度和做法。
设计/方法：2004年在劳森·威尔金斯儿科内分泌学会会议期间举办了一次关于青春期激素替代选择的研讨会。分发了一份问卷以调查与会者在诱导青春期方面的态度和做法。
大多数受访者使用结合雌激素治疗性腺功能减退的女孩，治疗的主要目的是达到最大成人身高。大多数受访者使用长效睾酮治疗性腺功能减退的男孩，治疗的主要目的是青春期发育和男性化。
建议使用生理性性激素替代疗法来优化性腺功能减退青少年的青春期诱导。研讨会揭示了美国和欧洲儿科内分泌学家在性腺功能减退女性青春期诱导的做法和态度上存在显著差异。需要进行详细研究以制定更统一的指南。
